Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance

Abstract

Today Cancer still remains a major cause of mortality and death worldwide, in humans. Chemotherapy, a key treatment strategy in cancer, has significant hurdles such as the occurrence of chemoresistance in cancer, which is inherent unresponsiveness or acquired upon exposure to chemotherapeutics. The resistance of cancer cells to an antineoplastic agent accompanied to other chemotherapeutic drugs with different structures and mechanisms of action called multi-drug resistance (MDR) plays an important role in the failure of chemo- therapeutics. MDR is primarily based on the overexpression of drug efflux pumps in the cellular membrane, which belongs to the ATP-binding cassette (ABC) superfamily of proteins, are P-gp (P-glycoprotein) and multidrug resistance-associated protein (MRP). Over the years, various strategies have been evaluated to overcome MDR, based not only on the use of MDR modulators but also on the implementation an innovative approach and advanced nanosized drug delivery systems. Nanomedicine is an emerging tool of chemotherapy that focuses on alternative drug delivery for improvement of the treatment efficacy and reducing side effects to normal tissues. This review aims to focus on the details biology, reversal strategies option with the limitation of MDR and various advantages of the present medical science nanotechnology with intracellular delivery aspects for overcoming the significant potential for improving the treatment of MDR malignancies.

Evaluation of cytotoxic effect of the combination of a pyridinyl carboxamide derivative and oxaliplatin on NCI-H1299 human non-small cell lung carcinoma cells

“…Overall, tumor cells of different colonies can be more sensible to chemotherapy agents. Although, proliferative tumor cells in a continuous exponential phase, are more susceptible to drugs [39]. The results showed that, the effect of the combination of LabMol-12 and oxaliplatin is more effective when the cells have a proliferative capacity.…”

Recent advancements in nanoparticles drug delivery systems

“…Therefore, developing nanomedicine applications in the future will need knowledge of the molecular fingerprints of illness. [40] More study is needed to increase the application of nanomedicine beyond what has been stated in review employing the currently existing nanoprobes and nanotheranostics devices.…”

Silencing long intergenic non‑coding RNA 00707 enhances cisplatin sensitivity in cisplatin‑resistant non‑small‑cell lung cancer cells by sponging miR‑145

“…Both MRP1 and P-gp are members of the superfamily of ATP-binding cassette transporters, which is involved in multidrug resistance. The increased expression of MRP1 and P-gp usually represents the enhancement of multidrug resistance (20). Therefore, the results of the present study suggest that LINC00707 knockdown enhances DDP sensitivity by weakening multidrug resistance.…”